Download our Presentation from our webinar Development of a Genetically-defined 3D Lung Cancer Model for Functional and Efficacy Studies

The dependence on existing cell-lines in drug development pipelines suffers from a lack of biological fidelity with the human disease, which is unique and complex. Use of 3D models with primary, genetically-defined cells allows for better functional and efficacy studies, capable of use in downstream applications, such as qPCR and immunostaining, in response to chemotherapeutic agents.

Download the presentation and you'll learn:

• Key Cellaria cell models and media currently available for your use
• The impact of the ORGANDOT™ format for assessing the effect of chemotherapeutic agents using primary cell models
• How to integrate primary cell, 3D cell models with downstream applications to generate complete drug sensitivity data packages, with established expected response to standard chemotherapeutics